Moneycontrol PRO
you are here: HomeNewsBiocon
business
Jump to
52 Results Found
  • US, Europe filings to drive Biocon growth: Kiran Mazumdar-Shaw May 24, 2016 10:11 AM IST

    US, Europe filings to drive Biocon growth: Kiran Mazumdar-Shaw

    These market filings have a market opportunity of USD 40 billion. In particular, Japan offers a market potential of USD 150 million for its insulin product Glargine, says Biocon's Chairman and Managing Director.

  • Realisations from insulin biosimilar to start from FY17: Biocon Mar 28, 2016 04:04 PM IST

    Realisations from insulin biosimilar to start from FY17: Biocon

    Getting approval to sell the biosimilar drug Glargine in Japan will open doors for the company, feels Kiran Mazumdar Shaw, Chairperson and Managing Director of Biocon.

  • Insulin mfg deal with Mexican co PISA to aid US mkt shr: Biocon Mar 17, 2016 10:00 AM IST

    Insulin mfg deal with Mexican co PISA to aid US mkt shr: Biocon

    Highlighting that the insulin market currently has just a handful of players and provides huge scope for growth, Kiran Mazumdar Shaw, CMD of Biocon says, the company will be filing its first insulin analogue dossier in FY17.

  • EU approval for making Rosuvastatin a key milestone: Biocon Feb 15, 2016 11:24 AM IST

    EU approval for making Rosuvastatin a key milestone: Biocon

    Kiran Mazumdar-Shaw, Chairman of the company, expects the company to soon win approval in the US as well.

  • US API import ban applies only to one drug: Biocon CMD Feb 05, 2016 10:30 AM IST

    US API import ban applies only to one drug: Biocon CMD

    The US government‘s decision to not allow overseas pharmaceutical companies to import active pharmaceutical ingredient (API) applies to only one particular anti retroviral drug and is not a blanket ban, Biocon CMD Kiran Mazumdar-Shaw said.

  • NeoBiocon partners with Novartis for diabetes drug in UAE Dec 10, 2015 10:00 AM IST

    NeoBiocon partners with Novartis for diabetes drug in UAE

    Speaking to CNBC-TV18, Dr Arun Chandavarkar, CEO & Joint MD, Biocon says that the company is also looking to introduce its biosimilars and insulin portfolio in the UAE.

  • 'There needs to be a serious rethinking on CBDT Proposal' Nov 23, 2015 09:53 PM IST

    'There needs to be a serious rethinking on CBDT Proposal'

    On Friday, the Central Bureau for Direct Taxes (CBDT) proposed a roadmap to bring corporate tax down from the current 30 percent to 25 percent by doing away with tax breaks to India Inc.

  • Eye 20% CAGR growth in future; expansion plans on: Syngene Sep 15, 2015 10:26 AM IST

    Eye 20% CAGR growth in future; expansion plans on: Syngene

    In an interview with CNBC-TV18, Peter Bains, CEO of Syngene International says that the company will invest nearly USD 100 million for a new plant in Mangalore, which will become functional in 2018.

  • Need clearer FII policy for India's novel start-ups: Biocon Aug 20, 2015 05:31 PM IST

    Need clearer FII policy for India's novel start-ups: Biocon

    Kiran Mazumdar Shaw, Chairman and MD, Biocon believes India‘s innovation led growth story is what investors are buying into but foreign investors need predictability and clarity in policies and regulations.

  • Major progress in IPR policy, should roll out yr-end:Biocon Jul 22, 2015 03:00 PM IST

    Major progress in IPR policy, should roll out yr-end:Biocon

    Kiran Mazumdar Shaw, CMD, Biocon says there is a need to protect interest and disallow monopolies like big pharma or big companies/ corporates that want to invest and take advantage of the Indian market.

  • Syngene listing likely by July, may offload 10%: Biocon Apr 22, 2015 06:09 PM IST

    Syngene listing likely by July, may offload 10%: Biocon

    Biocon will be offloading at least 10 percent of Syngene equity as it needs funds to support some of its R&D programmes.

  • Will get Syngene listed in FY16, to file DRHP in Q1: Biocon Apr 01, 2015 01:41 PM IST

    Will get Syngene listed in FY16, to file DRHP in Q1: Biocon

    Kiran Mazumdar Shaw, Chairperson and MD, Biocon also said that Syngene has good growth prospects and sound business plan and has a baseline valuation of Rs 3,800 crore.

  • FDA India scrutiny quality issue, no witch-hunt: Biocon CMD Mar 26, 2015 10:44 AM IST

    FDA India scrutiny quality issue, no witch-hunt: Biocon CMD

    Rubbishing concerns that the increasing FDA scrutiny of Indian pharma companieswas a case of "irrational clampdown", Biocon CMD Kiran Mazumdar-Shaw told CNBC-TV18 that the US regulator is mandating more stringent norms for companies across the world.

  • Biocon launches second-generation INSUpen EZ Oct 29, 2014 03:02 PM IST

    Biocon launches second-generation INSUpen EZ

    Biocon has launched INSUpen EZ, a second-generation insulin-delivery pen device, developed by Germany‘s Haselmeier. “This is a low-cost pen, which will help us penetrate the market in a bigger way,” CMD Kiran Mazumdar-Shaw told CNBC-TV18‘s Ekta Batra and Nigel D‘Souza.

  • Biosimilars is the next big thing for generic cos: Biocon Mar 07, 2014 03:27 PM IST

    Biosimilars is the next big thing for generic cos: Biocon

    Biocon CMD Kiran Mazumdar-Shaw said the company‘s research efforts are focused on a number of programs that deliver drugs that women can benefit from.

  • Don't see immediate revenue impact from Quark deal: Biocon Dec 20, 2013 11:30 AM IST

    Don't see immediate revenue impact from Quark deal: Biocon

    Biocon has inked a pact with California-based Quark Pharma to co-develop medicines based on the emerging siRNA technology.

  • To market Roche's cancer drug clone from FY14 end: Biocon Nov 25, 2013 10:18 AM IST

    To market Roche's cancer drug clone from FY14 end: Biocon

    Kiran Mazumdar Shaw, CMD, Biocon says the nod is for India marketing rights but opens up huge opportunities as the cancer drug has a market of USD 6 billion worldwide.

  • Biocon, Mylan in deal for 3 bio-generic insulin drugs Feb 14, 2013 10:31 AM IST

    Biocon, Mylan in deal for 3 bio-generic insulin drugs

    Biocon, a global biopharmaceutical enterprise today entered into a licencing agreement with Mylan for three bio-generic insulin products. Kiran Mazumdar, CMD, Biocon, in an interview to CNBC-TV18, says that the company will receive licencing fees from Mylan, however, they will not receive any milestone payments.

  • Biocon in pact with Bristol-Myers for 'blockbuster' drug Nov 16, 2012 09:26 AM IST

    Biocon in pact with Bristol-Myers for 'blockbuster' drug

    Biotech major Biocon has signed an option agreement with Bristol-Myers Squibb Company for Biocon‘s IN-105, a prandial oral insulin product candidate.

  • Biocon, Syngene set up 1st nutrition R&D centre Jun 04, 2012 02:01 PM IST

    Biocon, Syngene set up 1st nutrition R&D centre

    Drug firm Abbott today opened its first nutrition research and development center in the country in collaboration with Biocon's subsidiary Syngene.

  • No short-term revenue impact from split with Pfizer: Biocon Mar 13, 2012 10:50 AM IST

    No short-term revenue impact from split with Pfizer: Biocon

    In an exclusive interview to CNBC-TV18, Kiran Mazumdar Shaw of Biocon says that the breakup with Pfizer will not have any short-term impact on revenues for either company, but will reflect in the fourth quarter financials.

  • Biocon-Pfizer insulin deal might collapse soon: PharmAsia Mar 12, 2012 09:59 PM IST

    Biocon-Pfizer insulin deal might collapse soon: PharmAsia

    The deal between Biocon and Pfizer to market a range of insulin products may be in crisis. Vikas Dandekar, the India Bureau Chief of PharmAsia News who broke this story tells CNBC-TV18 that while sources are saying talks are on to salvage the deal, it is most likely to be called off.

  • Entrepreneurship lessons from Biocon's Kiran Mazumdar-Shaw Sep 24, 2011 04:25 PM IST

    Entrepreneurship lessons from Biocon's Kiran Mazumdar-Shaw

    India's largest listed biotechnology firm Biocon's chairperson and managing director Kiran Mazumdar-Shaw is one of India's most successful entrepreneurs.

  • Rupee depreciation to aid export margins, says Biocon Sep 14, 2011 12:04 PM IST

    Rupee depreciation to aid export margins, says Biocon

    Biocon chief Kiran Mazumdar-Shaw says that the research division is set to benefit from the fall in the value of rupee. "That apart, Biocon will see margin improvement in exports due to the rate differential," she says.

  • Real opportunity for Dificid to kick in 3-4 years: Biocon Jun 07, 2011 10:39 AM IST

    Real opportunity for Dificid to kick in 3-4 years: Biocon

    Kiran Mazumdar, CMD, Biocon in an interview with CNBC-TV18 speaking about the same said that Optimer is planning to launch within the next three- four months. So, in the short-term Biocon will have some contribution to the bottom line from these supplies.

Sections
ISO 27001 - BSI Assurance Mark